Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.54 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14303593 | 0.92 | KCNH2 (0.59) | KCNH2ENPP3ALPLENPP1XIAP | |
| SCHEMBL509165 | 0.90 | KCNH2 (0.58) | KCNH2ENPP3ALPLENPP1XIAP | |
| SCHEMBL4104852 | 0.84 | ENPP3 (0.55) | KCNH2ENPP3ALPLENPP1XIAP | |
| SCHEMBL4109187 | 0.83 | ENPP3 (0.50) | KCNH2ENPP3ALPLENPP1XIAP | |
| SCHEMBL5228264 | 0.82 | KCNH2 (0.49) | KCNH2ENPP3ALPLENPP1XIAP | |
| SCHEMBL509235 | 0.82 | KCNH2 (0.49) | KCNH2ENPP3ALPLENPP1XIAP | |
| SCHEMBL4715258 | 0.81 | KCNH2 (0.58) | KCNH2ENPP3ALPLENPP1XIAP | |
| SCHEMBL4766433 | 0.81 | KCNH2 (0.58) | KCNH2ENPP3ALPLENPP1XIAP | |
| SCHEMBL5176401 | 0.80 | KCNH2 (0.47) | KCNH2ENPP3ALPLENPP1XIAP | |
| SCHEMBL4772293 | 0.77 | KCNH2 (0.53) | KCNH2CYP3A4CYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556381-B1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1556381-B1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1551828-B1 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-6933312-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1556381-A1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | Pfizer Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| EP-1551828-A1 | PYRAZOLE DERIVATIVES | Pfizer Limited (GB) | 2005-07-13 | — | — | EP | disclosed |
| US-20050004129-A1 | Pyrazole derivatives | PFIZER, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040133002-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004031178-A1 | PYRAZOLE DERIVATIVES | PFIZER LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004029051-A1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133002-A1 | Pyrazole derivatives | REV1, RRS1, CYP2F1 | KCNH2 3181/4885ENPP3 1365/4885ALPL 2578/4885 |
| US-20050004129-A1 | Pyrazole derivatives | RTF1, RRM2B, RRM2 | KCNH2 2921/4885ENPP3 1100/4885ALPL 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.